logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy - Notice of GM and Posting of Circular

RNS Number : 2650K
Advanced Oncotherapy PLC
21 April 2020
 

21 April 2020

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

 Notice of general meeting and posting of circular

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to its announcements of 9 April 2020, the Company has published a Circular to convene a General Meeting of shareholders to propose resolutions to enable, inter alia, completion of the proposed Subscription.

 

The General Meeting will be held at 2.00 p.m. on 11 May 2020.

 

The Circular sets out arrangements for the General Meeting in light of the current British government restrictions placed on public gatherings in response to the COVID-19 outbreak. Under the current prohibition on non-essential travel and public gatherings, it will not be possible for Shareholders to attend the General Meeting in person. Shareholders are strongly urged to vote by proxy in advance of the deadline by completing their form of proxy in accordance with the instructions and further details are set out in the Circular and the form of proxy. 

 

The Circular will be posted today to shareholders and is available on the Company's website at www.avoplc.com.

 

The Company also announces that Admission, as referred to in the announcements of 07:00 a.m. and 07:30 a.m. on 9 April 2020, is expected to now take place on or around 13 May 2020 rather than 15 May 2020.

 

Capitalised terms in this announcement shall have the meanings given to such terms in the Company's announcements of 07:00 a.m. and 07:30 a.m. on 9 April 2020 unless defined otherwise herein.

 

- ENDS -

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO

 




Allenby Capital Limited (Nomad & Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

Tel: +44 (0) 20 3328 5656



 

FTI Consulting (Financial PR & IR)

 

[email protected]

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOGBIGDSRSDDGGG

Quick facts: Advanced Oncotherapy PLC

Price: 26.2

Market: LSE
Market Cap: £80.27 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Lloyds ends PPI headache; Sirius Minerals 'is quality' says...

Headlines from the Proactive UK newsroom. Anglo American (LON:AAL) has repeated that Sirius Minerals (LON:SXX) is a “quality” investment which is expected to “fit well” with the FTSE 100 group’s strategy. Anglo, which has made a bid for the firm, says the project in North Yorkshire is...

on 20/2/20